Publications

Search our bibliography using the filters on the right-hand side.

Displaying 101 through 150 of 223 publications.

Castellsague J, Calingaert B, Rothman KJ, Gutierrez L, van Herk-Sukel MPP, Kuiper JG, Pottegard A, Hallas J, Berglind IA, Sundstrom A, Dedman D, Gallagher A, Kaye JA, Pardo C, Perez-Gutthann S. Probabilistic bias analysis for unmeasured confounders in a study of users of topical tacrolimus, pimecrolimus, and corticosteroids (JOELLE) study. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):142-3.

Castellsague J, Kuiper JJG, Pottegard A, Berglind IA, Dedman D, Gutierrez L, Calingaert B, van Herk-Sukel MPP, Hallas J, Sundstrom A, Gallagher A, Kaye JA, Pardo C, Rothman KJ, Perez-Gutthann S. Risk of lymphoma in users of topical tacrolimus, pimecrolimus and corticosteroids (JOELLE study). Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):494-5.

Castellsague J, van Herk-Sukel MPP, Hallas J, Sundstrom A, Gallagher A, Gutierrez L, Calingaert B, Kuiper JG, Pottegard A, Berglind IA, Dedman D, Kaye JA, Pardo C, Rothman KJ, Perez-Gutthann S. Risk of skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids. JOint European Longitudinal Lymphoma and skin cancer Evaluation (JOELLE) study. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):527.

Castellsague J, Calingaert B, Poblador-Plou B, Giner-Soriano M, Linder M, Scholle O, Varas-Lorenzo C, Arana A, Bui C, Prados-Torres A, Gonzalez-Rubio F, Roso-Llorach A, Citarella A, Garbe E, Blenk T, Perez-Gutthann S. Characterization of new users of cilostazol in the United Kingdom, Spain, Sweden, and Germany. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):203-4.

Margulis A, Houben E, Olesen M, Hallas J, Overbeek J, Pottegard A, Ye W, Villegas D, Perez-Gutthann S, Arana A. Drug utilization study: evaluation of the use of nepafenac in the Netherlands and Denmark. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):225.

Margulis AV, Varas-Lorenzo C, Bui CL, McQuay LJ, Ziemiecki R, Reynolds M, Rebordosa C, Pladevall-Vila M, Fortuny J, Rivero-Ferrer E, Plana E, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S, Arana A. Validation of cardiovascular events and covariates in CPRD GOLD using questionnaires to general practitioners (GPS). Presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):255-6.

Margulis AV, Linder M, Arana A, Pottegard A, Anveden-Berglind I, Bui CL, Kristiansen NS, Bahmanya S, McQuay LJ, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S, Hallas J. Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):653.

Hallas J, Margulis AV, Pottegard A, Kristiansen N, Bui CL, Krueger W, Atsma WJ, Appenteng K, Franks B, de Vogel S, D 'Silva M, Perez-Gutthann S, Arana A. Incidence of cardiovascular events in new users of overactive bladder medications in Denmark. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):491.

Hallas J, Margulis AV, Pottegard A, Kaye JA, Kristiansen N, Bui CL, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S, Arana A. Elevated bladder and prostate cancer rates following initiation of OAB medication: findings from the Danish Registries. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):533.

Rebordosa C, Varas-Lorenzo C, Castellsague J, Plana E, Bui C, Aguado J, Garcia Gil E, Perez-Gutthann S. Characteristics of new users of aclidinium bromide in the United Kingdom. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):677. doi: 10.1002/pds.4070

Prados-Torres A, Poblador-Plou B, Gonzalez-Rubio F, Gimeno Miguel A, Castellsague J, Perez-Gutthann S, Arana A. The EpiChron Cohort proven useful for pharmacoepidemiological studies. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):399.

Fortuny J, Kaye JA, Bui CL, Gilsenan AW, Bartsch J, Plana E, McQuay LJ, Calingaert B, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez Gutthan S, Arana A, Margulis AV. Evaluation of free-text comments to validate common cancer diagnoses in the UK CPRD. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):58.

Linder M, Margulis AV, Anveden-Berglind I, Bahmanyar S, Bui CL, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S, Arana A. Cardiovascular risk in users of antimuscarinic drugs for overactive bladder: a cohort study in the Swedish National Registers. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):491-2.

Linder M, Margulis AV, Anveden-Berglind I, Bahmanyar S, Bui CL, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S, Arana A. Cancer risk in users of antimuscarinic drugs for overactive bladder: a cohort study in the Swedish National Registers. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):533-4.

Kuiper JG, van Herk-Sukel MPP, Castellsague J, Potttegard A, Berglind IA, Dedman D, Calingaert B, Hallas J, Sundstrom A, Gallagher AM, Kaye JA, Pardo C, Rothman KJ, Perez-Gutthann S. Utilization of tacrolimus and pimecrolimus in Europe: results from the JOint European Longitudinal Lymphoma and skin cancer Evaluation (JOELLE) study. Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):630-1.

Perez-Gutthann S. Pharmacoepidemiology overview & case study. Presented at the Oxford Epidemiology Summer School; July 12, 2016. Oxford, United Kingdom.

Pladevall M, Riera Guardia N, Margulis AV, Varas-Lorenzo C, Calingaert B, Perez-Gutthann S. Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies. BMC Cardiovasc Disord. 2016 Jan 15;16(1):14. doi: 10.1186/s12872-016-0187-5

Stein D, Weatherall M, Garratt C, Aantaa R, Conti G, Lewis MA, Moore N, Gutthann S. Methodological considerations for the implementation of a European mandated retrospective drug utilisation study (DUS) to investigate the use of dexmedetomidine (DEXDOR®) in clinical practice. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.

Perez-Gutthann S. Risk minimization evaluation studies: perspective of a research center. Presented at the Drug Information Association 9th European Forum for Qualified Persons Responsible For Pharmacovigilance; October 13, 2015. London, England.

Garratt C, Weatherall M, Pohjanjousi P, Aantao R, Conti G, Lewis M, Moore N, Perez-Gutthann S. A multinational, drug utilisation study to investigate the use of dexmedetomidine (DEXDOR®) in clinical practice in the EU. Poster presented at the 2015 ESICM's 28th Annual Congress; October 3, 2015. Berlin, Germany. [abstract] Intensive Care Med Exp. 2015 Oct 1; 3(Suppl 1):A322. Previously presented at the 31st ICPE International Conference on Pharmacoepidemiology and Therapeutic Risk Management. doi: 10.1186/2197-425X-3-S1-A322

Perez-Gutthann S. Role of the German pharmacoepidemiology research database in pharmacoepidemiology. Presented at the Leibniz Bremen Institute of Social and Preventive Medicine; September 17, 2015. Bremen, Germany.

Perez-Gutthann S. Overview of large healthcare databases. Presented at the London School of Hygiene and Tropical Medicine; September 14, 2015. London, United Kingdom.

Perez-Gutthann S, Weatherall M, Garratt C, Pohjanjousi P, Aantaa R, Conti G, Lewis M, Moore N. A multinational, drug utilisation study to investigate the use of dexmedetomidine (Dexdor®) in clinical practice in the EU. Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA. [abstract] Pharmacoepidemiol Drug Saf. 2015 Sep; 24(S1):95-6. doi: 10.1002/pds.3838

Masclee GMC, Valkoff VE, Straatman H, Herings R, Garbe E, Schink T, Kollhorst B, Arfe A, Lucchi S, Villa M, Castellsague J, Perez-Gutthann S, Varas-Lorenzo C, Schade R, Schuemie M, Vergouwe Y, Steyerberg E, Sturkenboom M, Romio S. Individualized NSAID prescribing based on gastrointestinal and cardiovascular risks: a decision model in the SOS project. Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA. [abstract] Pharmacoepidemiol Drug Saf. 2015 Sep; 24(S1):36-7. doi: 10.1002/pds.3838

Andrade S, Perez-Gutthann S, Hua W, Kawai A, Martin D, Reichman M, Toh D. Building a sustainable surveillance system to monitor the use and safety of medical products in pregnancy. Presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA. [abstract] Pharmacoepidemiol Drug Saf. 2015 Sep; 24(S1):239-40. doi: 10.1002/pds.3838

Kaye JA, Margulis AV, Plana E, Calingaert B, Perez-Gutthann S, Arana A. Cancer rates over time after initiation of overactive bladder drugs. Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA.

Perez-Gutthann S. A boney topic: bisphosphonate use and outcomes. Presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA.

Margulis AV, McQuay LJ, Perez-Gutthann S, Kaye JA, Arana A. Use of overactive bladder medications in the adult population of the UK: a cohort study in the Clinical Practice Research Datalink. Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA.

Fortuny J, Kaye JA, Margulis AV, Plana E, Calingaert B, Perez-Gutthann S, Arana A. Validity of cancer diagnoses in general practitioner medical records. Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA.

Masclee GMC, Straatman H, Herings R, Garbe E, Schink T, Kollhurst B, Arfe A, Lucchi S, Villa M, Castellsague J, Perez-Gutthann S, Varas-Lorenzo C, Romio S, Schade R, Schuemie MJ, Valkoff VE, Sturkenboom MCJM. Risk of acute myocardial infarction during use of individual NSAIDs: a nested case-control study in the SOS project. Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA.

Margulis AV, Pladevall M, Riera-Guardia N, Varas-Lorenzo C, Hazell L, Berkman ND, Viswanathan M, Perez-Gutthann S. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol. 2014 Oct 10;6:359-68. doi: 10.2147/CLEP.S66677

Moride Y, Andrews EB, Perez-Gutthann S, Soriano-Gabarró M, Heaton S, Suzart-Woischnik K, Vassilev Z, Raine JM. Challenges in risk minimization evaluation: CIOMS Working Group IX consensus and recent field experience. Presented at the 30th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; October 2014. Taipei, China. [abstract] Pharmacoepidemiol Drug Saf. 2014 Oct; 23(S1):41-2.

Hazell L, Pladevall-Vila M, Scotti L, De Berardis G, Varas-Lorenzo C, Perez-Gutthann S, Sturkenboom M, Shakir S. Diabetes drugs and acute pancreatitis: a systematic review of observational studies. Poster presented at the 30th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; October 2014. [abstract] Pharmacoepidemiol Drug Saf. 2014 Oct; 23(S1):277.

Varas-Lorenzo C, Margulis AV, Pladevall M, Riera-Guardia N, Calingaert B, Hazell L, Romio S, Perez-Gutthann S. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovasc Disord. 2014 Sep 26;14(1):129. doi: 10.1186/1471-2261-14-129

Kaye JA, Castellsague J, Bui CL, Calingaert B, McQuay LJ, Riera-Guardia N, Saltus CW, Quinlan S, Holick CN, Wahl PM, Suzart K, Rothman KJ, Wallander M-A, Perez-Gutthann S. Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study. Pharmacotherapy. 2014 Apr;34(4):336-49. doi: 10.1002/phar.1367

Bui CL, Kaye JA, Castellsague J, Calingaert B, McQuay LJ, Riera-Guardia N, Saltus CW, Quinlan SC, Holick CN, Wahl PM, Suzart K, Rothman KJ, Wallander MA, Perez-Gutthann S. Validation of acute liver injury cases in a population-based cohort study of oral antimicrobial users. Curr Drug Saf. 2014 Mar;9(1):23-8.

Pisa F, Castellsague J, Drigo D, Riera Guardia N, Giangreco M, Rosolen V, Clagnan E, Zanier L, Perez-Gutthann S, Barbone F. Accuracy of ICD-9-CM codes for upper gastrointestinal complications vaired by position and age: a validation study in a cohort of NSAID users in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf. 2013 Nov 22;22(11):1195-204. doi: 10.1002/pds.3504

Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Margulis A, Pladevall M, Miguel G, Romio S, Sturkenboom M, Perez-Gutthann S. Cardiovascular risk with glitazones and metformin: results from a systematic review of observational studies. Poster presented at the 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management; August 2013. [abstract] Pharmacoepidemiol Drug Saf. 2013 Oct 7; 22(S1):68.

Riera Guardia N, Margulis AV, Pladevall-Vila M, Varas-Lorenzo C, Perez-Gutthann S. Methods issues in observational studies of the cardiovascular risk associated with glucose-lowering medications: results of a systematic review and evaluation. Poster presented at the 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; October 7, 2013. [abstract] Pharmacoepidemiol Drug Saf. 22(Suppl 1):S80-81.

Pisa F, Castellsague J, Drigo D, Riera-Guardia N, Giangreco M, Rosolen V, Clagnan E, Zanier L, Perez-Gutthann S, Barbone F. Accuracy of International Classification of Diseases, 9th Revision, Clinical Modification codes for upper gastrointestinal complications varied by position and age: a validation study in a cohort of nonsteroidal anti-inflammatory drugs users in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf. 2013 Aug 20;22(11):1195-204.

Riera-Guardia N, Saltus CW, Bui CL, Harris DH, Kaye JA, Tennis P, Castellsague J, Perez-Gutthann S. Changes in the landscape of health care database research from 2000 to 2011. 2013. Research Triangle Park: RTI Press.

Pladevall M, Zografos L, Tatt I, Napalkov P, Andrews E, Perez-Gutthann S. Feasibility evaluation for a rituximab utilization study to be conducted in infusion centers. Poster presented at the 29th International Conference on Pharmacoepidemiology; August 2013.

Margulis AV, Pladevall-Vila M, Riera Guardia N, Varas-Lorenzo C, Hazell L, Perez-Gutthann S. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastele-Ottawa Scale and the RTI Item Bank. Poster presented at the 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management; August 2013.

Varas-Lorenzo C, Riera Guardia N, Castellsague J, Arfe A, Perez-Gutthann S. The SOS project: risk of heart failure and use of nonsteroidal anti-inflammatory drugs. A meta-analysis of observational studies. Poster presented at the 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2013. [abstract] Pharmacoepidemiol Drug Saf. 22(S1):67.

Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Salvo F, Nicotra F, Sturkenboom M, Perez-Gutthann S. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013 Jun;22(6):559-70.

Castellsague J, Pisa F, Rosolen V, Drigo D, Riera Guardia N, Giangreco M, Clagnan E, Tosolini F, Zanier L, Barbone F, Perez-Gutthann S. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf. 2013 Apr 22;22(4):365-75.

Perez-Gutthann S. Post-approval safety studies: impact of 2012 pv legislation & guidance. Poster presented at the DIA 7th European Forum for Qualified Person for Pharmacovigilance (QPPV); April 19, 2013.

Gulmez SE, Larrey D, Pageaux GP, Lignot-Maleyran S, de Vries C, Sturkenboom M, Perez-Gutthann S, Benichou J, Bissoli F, Horsmans Y, Bernuau J, Stricker B, Thorburn D, Blin P, Moore N. Methodology for a multinational case–population study on liver toxicity risks with NSAIDs: the Study of Acute Liver Transplant (SALT). Eur J Clin Pharmacol. 2013 Mar 1;69(3):605-16.

Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jove J, Gatta A, McCormick A, Metselaar HJ, Monteiro E, Thorburn D, Bernal W, Zouboulis-Vafiadis I, de Vries C, Perez-Gutthann S, Sturkenboom M, Benichou J, Montastruc JL, Horsmans Y, Salvo F, Hamoud F, Micon S, Droz-Perroteau C, Blin P, Moore N. Transplantation for acute liver failure in patients exposed to NSAIDs or Paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf. 2013 Feb 1;36(2):135-44.

Macdonald TM, Mackenzie IS, Wei L, Hawkey CJ, Ford I, Perez-Gutthann S. Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: protocol of the Standard care versus Celocoxib Outcome Trial (SCOT). BMJ Open. 2013 Jan 29;3(1):e002295. doi: 10.1136/bmjopen-2012-002295